These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
751 related articles for article (PubMed ID: 34835096)
1. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096 [TBL] [Abstract][Full Text] [Related]
2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
3. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity. Ramírez MA; Loaiza RA; Martínez-Balboa Y; Bruneau N; Ramírez E; González PA; Bueno SM; Kalergis AM Vaccine; 2024 Oct; 42(23):126203. PubMed ID: 39178767 [TBL] [Abstract][Full Text] [Related]
4. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509 [TBL] [Abstract][Full Text] [Related]
5. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2024; 15():1420304. PubMed ID: 39267752 [TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222 [TBL] [Abstract][Full Text] [Related]
7. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters. Hsieh M-S; Hsu C-W; Liao H-C; Lin C-L; Chiang C-Y; Chen M-Y; Liu S-J; Liao C-L; Chen H-W J Virol; 2024 Feb; 98(2):e0154623. PubMed ID: 38299865 [TBL] [Abstract][Full Text] [Related]
9. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
10. The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein. Mendoza-Ramírez NJ; García-Cordero J; Shrivastava G; Cedillo-Barrón L J Immunol Res; 2024; 2024():9313267. PubMed ID: 38939745 [TBL] [Abstract][Full Text] [Related]
11. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088 [TBL] [Abstract][Full Text] [Related]
12. Human CD4 Verhagen J; van der Meijden ED; Lang V; Kremer AE; Völkl S; Mackensen A; Aigner M; Kremer AN Clin Exp Immunol; 2021 Sep; 205(3):363-378. PubMed ID: 34061349 [TBL] [Abstract][Full Text] [Related]
13. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D Front Immunol; 2021; 12():719077. PubMed ID: 34394127 [TBL] [Abstract][Full Text] [Related]
14. Humoral and Cellular Immune Response to SARS-CoV-2 S and N Proteins. Afridonova ZE; Toptygina AP; Mikhaylov IS Biochemistry (Mosc); 2024 May; 89(5):872-882. PubMed ID: 38880648 [TBL] [Abstract][Full Text] [Related]
15. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N Front Immunol; 2022; 13():816220. PubMed ID: 35145522 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC mBio; 2021 Jan; 12(1):. PubMed ID: 33468695 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545 [TBL] [Abstract][Full Text] [Related]